|
1）Fuster V, Corti R, Fayad ZA, et al. Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. J Thromb Haemost. 2003; 1: 1410-21
|
|
|
|
2）Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998; 94: 657-66
|
|
|
|
|
|
3）Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000; 105: 783-91
|
|
|
|
|
|
4）冨山佳昭．血栓形成のメカニズムup-to-date. Angiology Frontier. 2007; 6: 11-7
|
|
|
|
|
5）Flamm MH, Colace TV, Chatterjee MS, et al. Multiscale prediction of patient-specific platelet function under flow. Blood. 2012; 120: 190-8
|
|
|
|
|
|
6）Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409: 202-7
|
|
|
|
|
|
7）Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001; 86: 222-32
|
|
|
|
|
|
8）Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004; 113: 340-5
|
|
|
|
|
|
9）Shiraga M, Miyata S, Kato H, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost. 2005; 3: 2315-23
|
|
|
|
|
|
10）Cattaneo M. Molecular defects of the platelet P2 receptors. Purinergic Signal. 2011; 7: 333-9
|
|
|
|
|
|
11）Cattaneo M. P2Y12 receptors: structure and function. J Thromb Haemost. 2015; 13 Suppl 1: S10-6
|
|
|
|
|
|
12）Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A. 2003; 100: 1978-83
|
|
|
|
|
|
13）Zhang K, Zhang J, Gao ZG, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014; 509: 115-8
|
|
|
|
|
|
14）Zhang J, Zhang K, Gao ZG, et al. Agonist-bound structure of the human P2Y12 receptor. Nature. 2014; 509: 119-22
|
|
|
|
|
|
15）大野耕作，武谷浩之．血小板ADP受容体P2Y12の立体構造．血栓止血誌．2014; 25: 742-7
|
|
|
|
|
16）Kamae T, Shiraga M, Kashiwagi H, et al. Critical role of ADP interaction with P2Y12 receptor in the maintenance of αIIbβ3 activation: association with Rap1B activation. J Thromb Haemost. 2006; 4: 1379-87
|
|
|
|
|
|
17）Tomiyama Y, Shiraga M, Kashiwagi H. Positive and negative regulation of integrin function, in Tanaka K, Davie EW, editors. Recent advances in thrombosis and hemostasis 2008. Japan: Springer; 2008. p.243-52
|
|
|
|
|
|
18）Stefanini L, Paul DS, Robledo RF, et al. RASA3 is a critical inhibitor of RAP1-dependent platelet activation. J Clin Invest. 2015; 125: 1419-32
|
|
|
|
|
|
19）CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329-39
|
|
|
|
|
|
20）Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-15
|
|
|
|
|
|
21）Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. 2008; 118: 1626-36
|
|
|
|
|
|
22）Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363-75
|
|
|
|
|
|
23）Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-62
|
|
|
|
|
|
24）Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008; 6: 1439-41
|
|
|
|
|
|
25）Jinnai T, Horiuchi H, Makiyama T, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J. 2009; 73: 1498-503
|
|
|
|
|
|
26）http: //www. fda. gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888. htm
|
|
|
|
|
|
27）Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119: 2553-60
|
|
|
|
|
|
28）Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304: 1821-30
|
|
|
|
|
|
29）Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011; 306: 2704-14
|
|
|
|
|
|
30）Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012; 125: 1276-87
|
|
|
|
|
|
31）Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation. 2012; 125: 1288-303
|
|
|
|
|
|
32）Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-57
|
|
|
|
|
|
33）Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361: 2318-29
|
|
|
|
|
|
34）Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013; 368: 1303-13
|
|
|
|
|